Open AccessDAPTOMYCIN THERAPY FAILURE IN AN ADOLESCENT WITH METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS BACTEREMIA
Author(s) -
Lara M. Jacobson,
Aaron M. Milstone,
Jonathan M. Zenilman,
Karen C. Carroll,
Ravit AravBoger
Publication year - 2009
Publication title -
the pediatric infectious disease journal/the pediatric infectious disease journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.028
H-Index - 140
eISSN - 1532-0987
pISSN - 0891-3668
DOI - 10.1097/inf.0b013e3181927891
Subject(s) - daptomycin , medicine , bacteremia , staphylococcus aureus , methicillin resistant staphylococcus aureus , vancomycin , staphylococcal infections , intensive care medicine , food and drug administration , antibiotics , microbiology and biotechnology , bacteria , pharmacology , biology , genetics
Daptomycin is a Food and Drug Administration-approved alternative to vancomycin for the treatment of serious methicillin-resistant Staphylococcus aureus infections in adults. Treatment failure with daptomycin is increasingly reported in adults, but data in children are limited. We report an adolescent patient with severe burn injuries who had persistent methicillin-resistant Staphylococcus aureus bacteremia and rapidly developed nonsusceptibility to daptomycin. We review the relevant literature.